RESUMO
Lung cancer in never-smokers (LCINS) (fewer than 100 cigarettes in lifetime) is considered as a distinct entity and harbours an original molecular profile. However, the epidemiological and molecular features of LCINS in Europe remain poorly understood. All consecutive newly diagnosed LCINS patients were included in this prospective observational study by 75 participating centres during a 14-month period. Each patient completed a detailed questionnaire about risk factor exposure. Biomarker and pathological analyses were also collected. We report the main descriptive overall results with a focus on sex differences. 384 patients were included: 65 men and 319 women. 66% had been exposed to passive smoking (significantly higher among women). Definite exposure to main occupational carcinogens was significantly higher in men (35% versus 8% in women). A targetable molecular alteration was found in 73% of patients (without any significant sex difference): EGFR in 51%, ALK in 8%, KRAS in 6%, HER2 in 3%, BRAF in 3%, PI3KCA in less than 1%, and multiple in 2%. We present the largest and most comprehensive LCINS analysis in a European population. Physicians should track occupational exposure in men (35%), and a somatic molecular alteration in both sexes (73%).
Assuntos
Neoplasias Pulmonares/epidemiologia , Neoplasias Pulmonares/genética , Idoso , Quinase do Linfoma Anaplásico , Biomarcadores/metabolismo , Carcinógenos , Estudos de Coortes , Receptores ErbB/genética , Feminino , França , Predisposição Genética para Doença , Humanos , Masculino , Pessoa de Meia-Idade , Proteínas Nucleares/genética , Doenças Profissionais/epidemiologia , Doenças Profissionais/genética , Exposição Ocupacional , Proteínas Proto-Oncogênicas B-raf/genética , Proteínas Proto-Oncogênicas p21(ras)/genética , Receptores Proteína Tirosina Quinases/genética , Receptor ErbB-2/genética , Fatores de Risco , Fatores Sexuais , Fumar , Inquéritos e Questionários , Poluição por Fumaça de Tabaco , Fatores de Transcrição/genéticaRESUMO
The annual prevalence of metastatic neuroendocrine tumours (mNETs) is rising, leading to significant healthcare costs. The present study aimed to describe healthcare resource use (HRU) and the corresponding costs among patients with mNETs, according to primary tumour location, functioning status and type of treatments. The LyREMeNET study included consecutive mNET patients with a diagnosis performed between January 2010 and December 2017, who were seen at least once in the ENETS center of excellence in Lyon. The median HRU and costs per patient were estimated, up to 3 years before and after the diagnosis. The Cancer database of the center was linked to the French national health data system. HRU and related costs were described per person per month (PPPM). Among 316 patients presenting with a mNET, 48.4% had a small-intestinal mNET, 32.3% had a pancreatic mNET and 39.2% had carcinoid syndrome. The mean overall cost increased from 615 to 2875 PPPM between the years preceding and following the diagnosis, and remained above 2500 in the two subsequent years. The two main cost drivers of total healthcare expenditure were drugs (1161) and hospital stay (662). Median costs of mNETs arising from pancreas and small intestine were 2325 and 2540 PPPM, respectively. Costs were higher in patients with a functional mNET (2807 PPPM for carcinoid syndrome) and during peptide receptor radionuclide therapy (PRRT) (8835 PPPM). The highest overall cost was found during the first year following the diagnosis. Cost of care was higher for small intestine mNETs, for functional mNETs and during peptide receptor radionuclide therapy.